Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 5NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Lung Neoplasms 9Glioblastoma 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 6Brenner Tumor 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Oligodendroglioma 3Carcinoma 3Astrocytoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mouth Neoplasms 2Medulloblastoma 2

Interventions

Cisplatin 23Radiotherapy 22Cetuximab 17Magnetic Resonance Spectroscopy 12Radiotherapy, Intensity-Modulated 10Fluorouracil 10Specimen Handling 9Platinum 91,2-diaminocyclohexaneplatinum II citrate 9pembrolizumab 8Erlotinib Hydrochloride 8Docetaxel 8Carboplatin 8Paclitaxel 7Biopsy 7Bevacizumab 7Radiation 5(225)Ac-DOTA-c(RGDyK) 5Hydroxyurea 4Gefitinib 4Radiosurgery 3Immunoglobulin G 3Disulfides 3Chemotherapy, Adjuvant 3Capecitabine 3ixabepilone 2dehydroftorafur 2atezolizumab 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Squamous Cell Carcinoma of Head and Neck × Disulfides × Clear all
NCT00588770 2026-05-26

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
403 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT05063552 2026-05-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡